Matsuo K, et al. - In this population-based retrospective study, researchers analyzed data from the 2001-2015 Nationwide Inpatient Sample to investigate the changes in performance and outcomes of pelvic exenteration for gynecologic malignancies—including cervical, uterine, vaginal, and vulvar malignancies. Participants included women with the aforementioned malignancies who underwent pelvic exenteration. Overall, 2,647 cases were included for comorbidity, perioperative complications, total charges, length of stay, and mortality. Most of the cases included cervical cancer (45.1%), followed by vaginal cancer (27.6%). Increases in obesity, as well as comorbidities, were noted during the study period in women undergoing pelvic exenteration for gynecologic malignancies. High morbidity and mortality, as well as substantial treatment-related costs, were offered by pelvic exenteration. Factors associated with an increased risk of multiple complications included more recent year of surgery, obesity, higher comorbidity, higher household income, surgery at large bed-size hospital, urinary diversion, vaginal reconstruction, and vulvar cancer.